Mycophenolatmofetil Stada (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycophenolatmofetil Stada, is an immunosuppressant presented as an oral formulation for oral use. It is used to prevent organ transplant rejection and to treat certain autoimmune diseases such as lupus nephritis in adult patients.

GNH USA supplies Mycophenolatmofetil Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

Mycophenolate Mofetil is employed in immunosuppressive regimens for organ transplantation and selected autoimmune disorders.

- Kidney transplant rejection: lowers the incidence of acute rejection episodes. - Heart transplant rejection: helps maintain graft function and prolong survival. - Lupus nephritis: contributes to remission of renal inflammation and preservation of kidney function.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, may lead to dehydration. - Headache: transient and usually resolves. - Abdominal pain: cramping or discomfort. - Infections: increased susceptibility to bacterial, viral or fungal infections.

Serious or Rare Side Effects: - Bone marrow suppression: leukopenia, anemia or thrombocytopenia. - Severe infections: opportunistic infections such as CMV or PCP. - Hepatic dysfunction: elevated transaminases or hepatitis. - Malignancy: increased risk of post‑transplant lymphoproliferative disorder. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease. - Pregnancy loss: potential teratogenic effects.

Careful monitoring and patient education are essential when using Mycophenolate Mofetil.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: check transaminases periodically. - Avoid live vaccines: immunosuppression can cause vaccine‑derived infection. - Pregnancy safety: discontinue if pregnancy is confirmed; discuss contraception. - Renal impairment: dose adjustment may be required in reduced kidney function. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil may interact with several concomitant medicines, influencing efficacy or toxicity.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Cyclosporine or tacrolimus: increased mycophenolic acid exposure, risk of toxicity. - Rifampin: markedly reduces mycophenolic acid levels, compromising efficacy.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours. - Warfarin: potential alteration of INR; monitor coagulation parameters. - Live attenuated vaccines: heightened risk of infection; consider alternative immunization strategies.